Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from global... Read More

Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 Conference call to review these data to be held at 8:30 a.m. ET today LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC . (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and... Read More

Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and consistent HiSCR responses were observed for placebo patients switching to active treatment Marked reductions in draining tunnels and skin pain also contributed to clinically meaningful improvements in quality of life Potential for... Read More

Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical responses achieved for the high hurdles of ACR70, PASI100, as well as composite endpoints ACR50/PASI100 and Minimal Disease Activity Favorable safety profile consistent with the IL-17A class and previous izokibep experience LOS... Read More

Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC . (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes... Read More

LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC . (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. “I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly... Read More

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in psoriatic arthritis (“PsA trial”). Background In September 2023, ACELYRIN... Read More

Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease expected in first quarter 2024 Additional PsA Phase 2 long-term data on clinical measures of disease resolution and quality of life to be presented at 2023 Annual Meeting of the American College of Rheumatology Cash, cash... Read More

Expands capacity for multi-asset manufacturing with highly accomplished supply chain, manufacturing and quality control leader bringing more than 25 years of biopharmaceutical experience across R&D, clinical and commercial supply management Joins at a pivotal time as ACELYRIN advances a robust portfolio of programs through late-stage clinical trials LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC . (Nasdaq:... Read More

LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its third quarter 2023 financial results and provide a corporate update. A live webcast of the conference call... Read More

Veteran drug developer and prior CMO from Novartis AG gene therapies brings decades of clinical experience including long tenure as Global Lead for secukinumab, which he advanced from early development through to approvals across multiple indications including Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa Strong complement to ACELYRIN’s current team and robust portfolio with multiple... Read More

The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis. HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to... Read More

LOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will participate in a moderated fireside chat during the Morgan Stanley 21 st Annual Global Healthcare Conference being held September 11-13,... Read More

New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the placebo-controlled Part B remains on track for top-line data in the third quarter 2023. Enrollment completed in Phase 2b/3 randomized controlled trial of izokibep in Psoriatic Arthritis; top-line data now accelerated to first quarter 2024... Read More

LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m. ET to discuss its second quarter 2023 financial results and provide a corporate update. A live webcast of the conference call... Read More

Accomplished global leader brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years. LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of... Read More

Initial Public Offering generated gross proceeds of $621 million;net proceeds of $573.7 million Strong cash position of $289.2 million at end of Q1 2023 $862.9 million from IPO net proceeds and existing cash balance on March 31, 2023 expected to fund key milestones across all three clinical programs Accelerated top-line data for P2b/3 randomized controlled study of izokibep in Hidradenitis Suppurativa (HS) from end of year,... Read More